News | February 27, 2026
Novo Nordisk & Vivtex team up to revolutionize oral hiologics
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
One of India’s top integrated contract research, development, and manufacturing organizations (CRDMOs) is on a hiring spree
This transaction fundamentally strengthens Scinai's CDMO platform
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
The proceeds from the ?IP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
